Clinical trial methodologies for disease-modifying therapeutic approaches

被引：15

作者：

Aisen, Paul S. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA

来源：

NEUROBIOLOGY OF AGING | 2011年 / 32卷

基金：

美国国家卫生研究院;

关键词：

Alzheimer's disease; Biomarkers; Clinical trials;

D O I：

10.1016/j.neurobiolaging.2011.09.008

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

In recent years, advances in Alzheimer's disease (AD) biomarker research have provided powerful tools to improve trial design. In particular, biomarkers provide powerful methods for the selection of individuals with Alzheimer's disease prior to the onset of dementia. Data suggest that neuroimaging biomarkers will be useful as endpoints for trials in very early, even asymptomatic disease, though further work is necessary to establish validity for regulatory purposes. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：S64 / S66

页数：3

共 8 条

[1] Alzheimer's disease therapeutic research: the path forward [J].

Aisen, Paul S. .

ALZHEIMERS RESEARCH & THERAPY, 2009, 1 (01)

[2] Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans [J].

Aisen, Paul S. ;

Petersen, Ronald C. ;

Donohue, Michael C. ;

Gamst, Anthony ;

Raman, Rema ;

Thomas, Ronald G. ;

Walter, Sarah ;

Trojanowski, John Q. ;

Shaw, Leslie M. ;

Beckett, Laurel A. ;

Jack, Clifford R., Jr. ;

Jagust, William ;

Toga, Arthur W. ;

Saykin, Andrew J. ;

Morris, John C. ;

Green, Robert C. ;

Weiner, Michael W. .

ALZHEIMERS & DEMENTIA, 2010, 6 (03) :239-246

[3] Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo [J].

Bateman, Randall J. ;

Munsell, Ling Y. ;

Morris, John C. ;

Swarm, Robert ;

Yarasheski, Kevin E. ;

Holtzman, David M. .

NATURE MEDICINE, 2006, 12 (07) :856-861

[4] A γ-Secretase Inhibitor Decreases Amyloid-β Production in the Central Nervous System [J].

Bateman, Randall J. ;

Siemers, Eric R. ;

Mawuenyega, Kwasi G. ;

Wen, Guolin ;

Browning, Karen R. ;

Sigurdson, Wendy C. ;

Yarasheski, Kevin E. ;

Friedrich, Stuart W. ;

DeMattos, Ronald B. ;

May, Patrick C. ;

Paul, Steven M. ;

Holtzman, David M. .

ANNALS OF NEUROLOGY, 2009, 66 (01) :48-54

[5] Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade [J].

Jack, Clifford R., Jr. ;

Knopman, David S. ;

Jagust, William J. ;

Shaw, Leslie M. ;

Aisen, Paul S. ;

Weiner, Michael W. ;

Petersen, Ronald C. ;

Trojanowski, John Q. .

LANCET NEUROLOGY, 2010, 9 (01) :119-128

[6] Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization [J].

Petersen, R. C. ;

Aisen, P. S. ;

Beckett, L. A. ;

Donohue, M. C. ;

Gamst, A. C. ;

Harvey, D. J. ;

Jack, C. R., Jr. ;

Jagust, W. J. ;

Shaw, L. M. ;

Toga, A. W. ;

Trojanowski, J. Q. ;

Weiner, M. W. .

NEUROLOGY, 2010, 74 (03) :201-209

[7] 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study [J].

Rinne, Juha O. ;

Brooks, David J. ;

Rossor, Martin N. ;

Fox, Nick C. ;

Bullock, Roger ;

Klunk, William E. ;

Mathis, Chester A. ;

Blennow, Kaj ;

Barakos, Jerome ;

Okello, Aren A. ;

de Llano, Sofia Rodriguez Martinez ;

Liu, Enchi ;

Koller, Martin ;

Gregg, Keith M. ;

Schenk, Dale ;

Black, Ronald ;

Grundman, Michael .

LANCET NEUROLOGY, 2010, 9 (04) :363-372

[8] Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease [J].

Siemers, Eric R. ;

Friedrich, Stuart ;

Dean, Robert A. ;

Gonzales, Celedon R. ;

Farlow, Martin R. ;

Paul, Steven M. ;

DeMattos, Ronald B. .

CLINICAL NEUROPHARMACOLOGY, 2010, 33 (02) :67-73

← 1 →